Home › Activist investors › Scopia Capital
Campaign activist. Positions and campaigns from Scopia Capital’s SEC filings. Updated November 20, 2026.
No active campaign by this definition (see How to read this).
No current position by this definition.
Campaigns are compiled from SEC filings (13D, proxy contest filings and settlement 8-Ks); campaigns run without SEC filings, e.g. by public letter below the 5% threshold, may not appear.
| Company | Outcome or last status | Date | First filing | Highest stage | Filings | Meeting / votes |
|---|---|---|---|---|---|---|
| Harmonic Inc | Stake reported below 5% | Jul 12, 2024 | Mar 8, 2021 | — | latest (7) | — |
| Acorda Therapeutics Inc | Settled (agreement with the company) | Feb 28, 2018 | Aug 7, 2017 | — | latest (2) | — |
| Itron Inc /Wa/ | Settled (agreement with the company) | Dec 11, 2015 | Dec 11, 2015 | — | latest (1) | — |
| Company | Last stake | Source | Outcome | Date |
|---|---|---|---|---|
| Harmonic Inc | 3.3% | Schedule 13D/A, filed Jul 12, 2024 | Reported below 5% in a 13D/A | Jul 12, 2024 |
Fund votes come from Form N-PX filings, which this site holds from July 1, 2023 (meetings through June 30, 2026; later meetings appear when the managers file their next N-PX); earlier contests and campaigns that settled before a vote are listed under the activist’s campaigns.
No proxy contest has gone to a vote since July 1, 2023.
How each campaign on record ended, as read from the filings: settlements disclosed in the company’s 8-K or the investor’s 13D, contested votes (8-K Item 5.07), withdrawals and 13D amendments below 5%.
| Company | Outcome | Detail | Date | First filing |
|---|---|---|---|---|
| Harmonic Inc | Settlement | agreement with the company | Mar 29, 2022 | Mar 8, 2021 |
| Acorda Therapeutics Inc | Settlement | agreement with the company | Feb 28, 2018 | Aug 7, 2017 |
| Itron Inc /Wa/ | Settlement | agreement with the company | Dec 11, 2015 | Dec 11, 2015 |
The change in the company’s closing share price from the first trading day on or before the investor’s first Schedule 13D to the latest close, and to 6 and 12 months after it, beside the S&P 500 (SPY) over the same dates. This is a price change after a filing date: it is not attributed to the investor, and it is not the investor’s return. Coverage: 0 of 1 13D positions have prices (the site’s daily price history starts November 10, 2025, and covers only listed tickers it tracks).
Terms of the cooperation agreements, read by rules from the company’s Form 8-K (or the investor’s 13D where it describes the agreement). Each term is quoted from the filing; terms a rule did not find are not listed, so a missing term is not evidence that the agreement lacks it.
“Upon the recommendation of the Scopia Director nominee by the Nominations Committee, the Board shall vote on the appointment of such Scopia Director to the Board as promptly as practicable after the Nominations Committee recommendation of such Scopia Director; provided , however , that if the Board does not elect such Scopia Director to the Board as a result of such person not meeting the Director Criteria, the Parties shall continue to follow the procedures of this Section 1…” 8-K, Feb 28, 2018
“…ue $0.01 per share, of the Company (the “ Common Stock ”), which represents approximately 18.1% of the issued and outstanding shares of Common Stock; and WHEREAS, the Company and Scopia have determined to come to an agreement regarding the appointment of the Scopia Directors (as defined below) to the board of directors of the Company (the “ Board ”) following the Company’s 2018 Annual Meeting of Stockholders (including any adjournment or postponement thereof or any special me…” 8-K, Feb 28, 2018
“…t to any publicly available information, including information in documents filed with the SEC), would result in such Third Party, together with its affiliates and associates, owning, controlling or otherwise having any beneficial or other ownership interest in the aggregate of more than 4.9% of the shares of Common Stock outstanding at such time or would increase the beneficial or other ownership interest of any Third Party who, together with its affiliates and associates, h…” 8-K, Feb 28, 2018
“In the event the Nominations Committee does not accept a person designated by Scopia as a Scopia Director as a result of such person not meeting the Director Criteria, Scopia shall have the right to recommend additional person(s) meeting the Director Criteria whose appointment shall be subject to the Nominations Committee recommending such person in accordance with the procedures described above.” 8-K, Feb 28, 2018
“…, corporation (including not-for-profit), general or limited partnership, limited liability or unlimited liability company, joint venture, estate, trust, association, organization or other entity of any kind or nature; and (iii) the term “ Standstill Period ” shall mean the period commencing on the date hereof and ending on the earlier of (i) January 1, 2019 and (ii) the date that is 15 business days prior to the deadline for the submission of stockholder nominations of direc…” 8-K, Feb 28, 2018
“In addition and to the extent set forth in the agreement, Scopia will support the Acorda Board of Directors’ slate of nominees at the 2018 Annual Meeting and abide by customary standstill and other provisions through January 1, 2019.” 8-K, Feb 28, 2018